{"url_path":"/sec/inmb/8-k/2026-06-17/item-5-02","section_key":"item-5-02","section_title":"Item 5.02 Departure of Directors or Certain Officers;","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-17","source_url":"https://www.sec.gov/Archives/edgar/data/1711754/0001213900-26-069611-index.html","accession_number":"0001213900-26-069611","cik":"0001711754","ticker":"INMB","issuer_name":"Inmune Bio, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1711754/0001213900-26-069611-index.html","primary_entity_key":"0001711754","primary_entity_name":"Inmune Bio, Inc."},"word_count":302,"has_tables":true,"body_markdown":"**Item 5.02 Departure of Directors or Certain Officers;\nElection of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**\n\n \n\nAs noted in Item 5.07 below, on June 16, 2026, INmune\nBio Inc. (the “Company”), held its annual meeting of stockholders (the “Annual Meeting”), where the stockholders\nof the Company approved the Company’s Third Amended and Restated 2021 Stock Incentive Plan (the “Amended Plan”), pursuant\nto which the shares of the Company’s common stock issuable under the Company’s Amended and Restated 2021 Stock Incentive Plan\nwas increased from 6,500,000 shares to 9,158,525 shares. In addition, the stockholders approved to implement an evergreen provision\nfor the purpose of increasing the number of shares of common stock reserved for the grant of Awards under the Amended Plan automatically\non the first trading day of each calendar year beginning with calendar year 2027 through and including the first trading day\nof calendar year 2031 by the lesser of: (A) 10.0% of the total number of shares of our common stock outstanding on December 31\nof the immediately preceding calendar year or (B) such smaller number of shares as is determined by the Company’s board of\ndirectors. The Amended Plan was previously approved by the Company’s board of directors and as noted below was approved by the Company’s\nstockholders at the Annual Meeting.\n\n \n\nFor a description of the material terms of the Amended\nPlan, see Proposal No. 3 in the Company’s Definitive Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission\non April 23, 2026 (the “Proxy Statement”), which description is incorporated herein by reference. The descriptions of\nthe Amended Plan contained herein and in the Proxy Statement, are qualified in their entirety by reference to the full text of the Amended\nPlan, a copy of which is filed hereto as Exhibit 10.1."}